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REVIEW
Misregulation of the proline rich 
homeodomain (PRH/HHEX) protein in cancer 
cells and its consequences for tumour growth 
and invasion
Kevin Gaston1* , Maria‑Angela Tsitsilianos1, Kerry Wadey1 and Padma‑Sheela Jayaraman2
Abstract 
The proline rich homeodomain protein (PRH), also known as haematopoietically expressed homeobox (HHEX), is an 
essential transcription factor in embryonic development and in the adult. The PRH protein forms oligomeric com‑
plexes that bind to tandemly repeated PRH recognition sequences within or at a distance from PRH‑target genes and 
recruit a variety of PRH‑interacting proteins. PRH can also bind to other transcription factors and co‑regulate specific 
target genes either directly through DNA binding, or indirectly through effects on the activity of its partner proteins. 
In addition, like some other homeodomain proteins, PRH can regulate the translation of specific mRNAs. Altered PRH 
expression and altered PRH intracellular localisation, are associated with breast cancer, liver cancer and thyroid cancer 
and some subtypes of leukaemia. This is consistent with the involvement of multiple PRH‑interacting proteins, includ‑
ing the oncoprotein c‑Myc, translation initiation factor 4E (eIF4E), and the promyelocytic leukaemia protein (PML), in 
the control of cell proliferation and cell survival. Similarly, multiple PRH target genes, including the genes encoding 
vascular endothelial growth factor (VEGF), VEGF receptors, Endoglin, and Goosecoid, are known to be important in 
the control of cell proliferation and cell survival and/or the regulation of cell migration and invasion. In this review, 
we summarise the evidence that implicates PRH in tumourigenesis and we review the data that suggests PRH levels 
could be useful in cancer prognosis and in the choice of treatment options.
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Background
The proline rich homeodomain protein/haematopoieti-
cally expressed homeobox (PRH/HHEX), is a transcrip-
tion factor encoded by the HHEX gene [1–3]. Although 
PRH was first identified in haematopoietic cells and it 
plays an important role in haematopoietic cell differen-
tiation, the protein is expressed in a wide range of cell 
types in the embryo and the adult. During embryogen-
esis PRH is required for the development of multiple 
organ systems (including the forebrain, heart, liver, thy-
roid and thymus); it is also required at earlier points in 
embryonic development for the generation of the anter-
oposterior axis [4–19]. Thus, PRH knockout mice have 
a wide variety of defects including defective forebrain 
formation, liver formation, vasculogenesis and haemat-
opoiesis and they are unable to survive gestation [4–6]. 
Analysis of RNA and protein in the adult indicates that 
PRH is widely expressed in many tissues including the 
haematopoietic compartment where it is preferentially 
expressed in myeloid cells but absent in T-lymphocytes. 
The importance of PRH in myeloid cells and leukaemia 
has been reviewed in detail previously [20] and recent 
studies implicate PRH in a number of other disease states 
including diabetes [21, 22]. Here we focus on the role of 
PRH in tumourigenesis and tumour cell biology.
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PRH structure
PRH is a 270 amino acid protein encoded by the orphan 
homeobox HHEX gene located on human chromosome 
10. The PRH protein has a predicted molecular mass 
of 30  kDa, but in  vivo and in  vitro PRH forms homo-
oligomeric complexes that appear to be octameric and 
hexadecameric [23–25]. These complexes are highly sta-
ble in  vitro resisting denaturation by temperature and 
chemical agents [26]. The PRH monomer has three func-
tional domains: a 136 amino acid N-terminal glycine-, 
alanine- and proline-rich domain, a central 60 amino acid 
proline-rich homeodomain, and a 73 amino acid acidic 
C-terminal domain (Fig. 1). The N-terminal domain can 
repress transcription when tethered to a heterologous 
DNA-binding domain [27]. The homeodomain mediates 
sequence-specific DNA binding [1, 24]. The C-terminal 
domain is required for the transcriptional activation of 
the sodium-dependent bile acid co-transporter (NTCP) 
gene and is therefore likely to be required for the activa-
tion of transcription in other contexts [28, 29].
PRH oligomerisation and DNA binding
The isolated PRH N-terminal domain is an SDS (sodium 
dodecyl sulphate)-resistant dimer that lacks extensive 
α-helical or β-sheet secondary structure [23]. The N-ter-
minal domain interacts with the PRH homeodomain and 
this facilitates oligomerisation [23]. Oligomerisation of 
PRH in cells has been demonstrated by in vivo cross-link-
ing and in vitro gel filtration chromatography and analyt-
ical ultracentrifugation experiments imply formation of 
octameric and hexadecameric species [23]. The isolated 
PRH homeodomain binds to short DNA motifs, typical 
of homeodomain binding sites, and a truncated protein, 
lacking the N-terminal domain, binds to DNA sequences 
with the consensus 5′ C/TA/TATTAAA/G 3′ [1, 24]. In con-
trast, the full length PRH protein binds with high affin-
ity and specificity to tandem arrays of sequences related 
to these motifs [24]. Several PRH target genes contain 
tandem arrays of consensus and non-consensus PRH 
binding sites [24]. The Goosecoid promoter for example 
contains an array of PRH binding sites and PRH binding 
to this DNA has been shown to induce DNA condensa-
tion suggestive of the formation of a nucleosome-like 
octameric complex with wrapped DNA [24, 25]. How-
ever, DNA condensation is not sufficient for the regu-
lation of transcription by PRH [25]. PRH can also be 
recruited to target genes via protein–protein interactions 
with other DNA binding proteins.
The regulation of PRH expression
Transcriptional regulation of the Prh/HHEX gene is 
required for precise temporal and spatial distribution 
of gene expression, particularly in the context of early 
development and attaining cell-type specificity. Several 
regulatory elements—either intronic or situated in the 
5′ flanking region of the Prh/HHEX gene—have been 
identified, as well as putative or experimentally estab-
lished regulatory proteins and signalling pathways. One 
such regulator is the Sp family of transcription factors: 
in MH1C1 rat hepatoma and K562 human erythroleuke-
mia cells, Sp1 and Sp3 bind GC-rich regions within the 
5′ flanking region of the Prh/HHEX gene and activate 
transcription [31]. These elements appear to be cell-type 
specific since they are not functional in all cell types [32]. 
Similarly, GATA-1, GATA-2 and c-Myb activate Prh/
HHEX transcription via intronic haematopoietic cell-
specific enhancer-like elements [33] and the Thyroid 
follicular cell-specific transcription factors TTF-1 and 
Pax8 also activate Prh/HHEX promoter activity in a cell 
type specific manner [34, 35]. Additionally PRH activates 
transcription at its own promoter in a positive regulatory 
feedback loop [34, 35]. Further examples of regulatory fac-
tors include HNF3β and GATA-4 which activate the Prh/
HHEX promoter in liver-derived HepG2 cells [36]. It is 
likely that cancer-associated changes in transcription fac-
tor activity result in altered PRH expression. However, the 
precise nature of the misregulation is expected to vary in 
different cancer types. In early development, Prh/HHEX 
expression is modulated by Wnt/β-catenin, transforming 
growth factor β (TGFβ), fibroblast growth factor (FGF) 
and bone morphogenetic protein (BMP)-mediated sig-
nalling pathways [18, 37–40]. The impact of these signal-
ling pathways on Prh/HHEX expression in tumour cells 
and the effects of cancer-associated changes in signalling 
Fig. 1 The PRH/HHEX protein and its interacting proteins. A 
diagrammatic representation of the human PRH protein. The PRH 
protein has three functional domains. The boxed and bracketed areas 
represent the regions of PRH that interact with the proteins indicated. 
The brackets indicate poorly mapped interactions. The filled circles 
represent residues that are phosphorylated by CK2 [30, 46‑48, 51, 52, 
54, 66, 76]
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are very poorly understood. Recent work has shown that 
elevated Prh/HHEX expression occurs in Early T cell pro-
genitor acute lymphoblastic leukaemia (ETP-ALL) and 
that this gene is a direct target of the LMO2 oncoprotein 
[41, 42]. Prh/HHEX transcription is activated by a triad of 
factors LMO2/FLI1/ERG bound at an intronic enhancer 
[42] and, additionally, chromatin immunoprecipitation 
experiments showed enrichment of LMO2, LDB1, LYL1, 
and GATA3 at the promoter and enhancer suggesting 
specific occupancy by these factors [41].
The regulation of transcription by PRH
Like several other transcription factors PRH can acti-
vate or repress gene expression depending on the target 
gene (Table  1). PRH-repressed genes include chordin 
(CHRD), Goosecoid (GSC), endothelial cell-specific mol-
ecule 1 (ESM1), vascular endothelial growth factor A 
(VEGFA), and thyroglobulin (TG) [10, 43–45]. As might 
be expected, PRH has a variety of interacting proteins 
many of which are transcription factors (Fig. 1). PRH can 
repress transcription of target genes via the recruitment 
of members of the Groucho/TLE family of co-repressor 
proteins. An engrailed homology 1 (Eh-1) motif (30—
TPFYIEDILD—39) within the N-terminal PRH repres-
sion domain interacts with the TLE1 Q-domain and 
C-terminal WD repeat domain. Mutation of phenyla-
lanine 32 to glutamic acid (PRH F32E) negates these 
contacts and inhibits repression by PRH [27, 46]. How-
ever, PRH can also repress transcription by competing 
with the TATA box binding protein (TBP) for binding to 
TATA box sequences and by interacting with other tran-
scription activators. For example, PRH binds to GATA-2 
and prevents GATA-2 from activating transcription of 
the KDR gene encoding VEGFR2 [47]. Similarly, PRH 
binds to Jun and inhibits Jun-dependent transcriptional 
activation of the basic fibroblast growth factor (bFGF) 
gene FGF2 [48].
PRH activates transcription of multiple genes include 
the genes encoding the TGFβ co-receptor Endoglin 
(ENG) [49], the Na(+)-bile acid cotransporter (NTCP/
SLC10A1) [28] and the L-type pyruvate kinase (L-PK/
PKLR) [50]. PRH activates transcription through multi-
ple mechanisms via direct binding to promoter regions, 
as in the case of the NTCP promoter [28], or through 
association with other transcription factors to act as a 
transcriptional co-activator. For example, PRH interacts 
with hepatocyte nuclear factor 1α (HNF-1α) to pro-
mote HNF-1α-dependent transcriptional activation of 
L-PK [50]. Similarly, the interaction of PRH and serum-
response factor (SRF) results in the activation of smooth 
muscle α-actin transcription via increased binding of SRF 
to DNA [51].
Post‑transcriptional regulation of gene expression by PRH
PRH can repress the transport of specific mRNAs via 
interaction with translation initiation factor 4E (eIF4E), 
thus inhibiting the translation of specific proteins [52]. 
PRH binds to eIF-4E in promyelocytic leukaemia protein 
(PML) nuclear bodies, inhibiting eIF-4E-mediated nucle-
ocytoplasmic transport of transcripts including cyclin D1 
[52]. Ectopic expression of PRH can disrupt PML nuclear 
bodies and block eIF-4E-dependent transport of cyclin 
D1 mRNA resulting in reduced cyclin D1 protein expres-
sion in leukaemic cell lines [52].
The regulation of PRH activity by protein kinase CK2
Protein kinase CK2 (previously casein kinase 2) is a ubiq-
uitously expressed enzyme implicated in a diverse range 
of cellular functions and processes including cell cycle 
progression [53]. CK2 is a serine/threonine kinase with 
the consensus target sequence S/T–X–X–D/E/pS (where 
X indicates any non-basic amino acid). CK2 exists as a 
heterotetrameric holoenzyme consisting of two cata-
lytic α subunits and two regulatory β subunits. The PRH 
N-terminal repression domain binds to the β subunit of 
CK2 and CK2 phosphorylates two residues (S163 and 
S177) within the PRH homeodomain [54]. Phosphoryla-
tion at these sites inhibits PRH DNA-binding in  vitro 
and in cells, and blocks the transcriptional regulation 
of PRH target genes [54, 55]. Furthermore, incubation 
of K562 cells with the translation inhibitor anisomycin 
indicated that hypo-phosphorylated PRH is longer lived 
Table 1 Direct PRH target genes associated with cancer
Target gene Function and pathways Regulation Evidence References
ENG (Endoglin/CD105) TGFβ co‑receptor: neoangiogenesis, cell invasion, metastasis, cell proliferation Activated ChIP, EMSA [49]
ESM1 (ESM‑1/Endocan) Cell–cell contacts: neoangiogenesis, metastasis, cell proliferation Repressed ChIP, EMSA [43]
GSC (Goosecoid) Transcription factor: epithelial‑mesechymal transition Repressed ChIP, EMSA [10, 24]
KDR (FLK1/VEGFR2) VEGF receptor: neoangiogenesis, cell invasion, metastasis, cell proliferation Repressed ChIP, EMSA [44]
VEGFA (VEGF/VPF) Growth factor: neoangiogenesis, cell invasion, metastasis, cell proliferation Repressed ChIP, EMSA [44]
FLT1 (VEGFR1) VEGF receptor: neoangiogenesis, cell invasion, metastasis, cell proliferation Repressed ChIP, EMSA [44]
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than hyper-phosphorylated pPRH, and that expression 
of the latter is prolonged by treatment with the protea-
some inhibitors MG132 and Lactacystin [55]. Thus, it 
appears that phosphorylation of PRH by CK2 targets the 
protein for proteasome-mediated cleavage. Interestingly, 
one cleavage product is a stable truncated PRH protein 
that lacks the C-terminal domain (PRHΔC), and this 
appears to operate as a transdominant negative regula-
tor of full-length PRH by sequestering TLE co-repressor 
proteins [55]. Expression of PRHΔC leads to increased 
expression of target genes repressed by PRH including 
FLT1 (VegfR1), suggesting that the presence of PRHΔC 
could antagonise the inhibitory effects of PRH on cell 
proliferation.
PRH in haematopoiesis and leukaemia
PRH is required for haematopoietic cell differentiation 
[56] at multiple stages of the differentiation process, 
reviewed in [20, 57]. Studies using embryoid body dif-
ferentiation and blastocyst complementation have dem-
onstrated critical roles for PRH in the development of 
definitive haematopoietic stem cells (HSCs) and B-cells 
[58–61]. Conditional knockout mice (Mx-Cre and Vav-
Cre) revealed broadly similar results namely that HHEX 
is not required for maintenance of adult HSCs and mye-
loid lineages either postnatally, or at later time points, 
but is essential for the commitment of multiple lymphoid 
lineages at the stage of the common lymphoid progeni-
tor. Although there are some differences between the 
two models presumably because of differences in Cre 
induction and the timing of knockout, both models show 
decreased expression of cyclin D1 and effects on lym-
phopoiesis [62, 63]. This decrease in cyclin D1 expression 
with HHEX knockout is also observed in ES cell derived 
haematopoietc colonies [61]. Overexpression of cyclin 
D1 in progenitor cell populations after inducible knock 
out (Mx-Cre) of HHEX rescues the B-cell developmen-
tal potential of PRH-null lymphoid precursors. Thus, 
PRH appears to regulate early lymphoid development 
by increasing cyclin D1 expression [62, 63]. Interestingly 
under conditions of stress haematopoiesis, that is, after 
sub-lethal irradiation, deletion of HHEX results in an 
inability of bone marrow cells to contribute to all bone 
marrow lineages as well as alterations in the proportion 
of long term and short stem cells, increased proliferation 
in vivo of stem cells and progenitors, and defects in T-cell 
populations [63].
PRH is implicated in several subtypes of leukaemia. 
Confocal microscopy and Western blot analysis dem-
onstrate a substantial decrease in PRH protein levels 
and decreased nuclear localization of PRH in 13 of 13 
primary AML (French American British classification 
M4/M5) and seven of seven blast crisis CML (bcCML) 
specimens but not in 11 of 11 M1/M2 AML, seven of 
eight acute lymphoid leukemia (ALL) specimens, or 
two of two chronic-phase CML [64]. Over-expression of 
eIF-4E transforms rat embryo fibroblasts and increased 
levels of this protein have been found in AML M4/M5 
subtypes [64]. PRH binds to eIF-4E disrupting eIF4E 
nuclear bodies and repressing mRNA transport of eIF-4E 
targets such as cyclin D1 mRNA; in U937 human leuke-
mic cells this results in the inhibition of cell proliferation 
[52, 64]. Thus PRH is a post-transcriptional repressor of 
cyclin D1 protein expression in leukaemic cells. The posi-
tive regulation of cyclin D1 mRNA expression by PRH 
inferred from knock out mouse experiments [61–63] is in 
contrast to the negative regulation of cyclin D1 protein 
expression in leukaemic cell lines. This apparent contra-
diction may be related to the lineage/differentiation state 
of the transformed cells compared to untransformed pro-
genitors in vivo or it may indicate a subtle mechanism for 
the fine-tuning of cyclin D1 expression by PRH.
In keeping with an inhibitory role of PRH on the prolif-
eration and transformation of leukaemic cells of myeloid 
origin, [44, 64–67] PRH directly represses the transcrip-
tion of multiple genes involved in VEGF-signalling in leu-
kaemic K562 cells. PRH knockdown in K562 cells results 
in increased transcription of these genes and increased 
VEGF autocrine signalling leading to increased cell sur-
vival [44]. These genes are regulated by PRH in other 
cells types: in endothelial cells, PRH has been shown 
to repress VegfR2 transcription although, in this case, 
repression is via an interaction with the transcription 
factor GATA-2 [47]. The derepression of these genes fol-
lowing PRH down-regulation is likely to be important in 
tumourigenesis.
Perturbation of the subcellular localisation of endog-
enous PRH has been proposed to be involved in the 
development of acute promyelocytic leukaemia (APL). 
The PML tumour suppressor protein regulates cellular 
signalling pathways controlling cell proliferation, apopto-
sis and senescence; PML can also interact with and nega-
tively regulate eIF4E [68]. Chromosomal rearrangements 
observed in APL produce fusion proteins between PML 
and retinoic acid receptor α (RARα) [69]. PRH interacts 
with PML independently of its interaction with eIF-4E, 
and PRH over-expression disrupts PML nuclear bodies 
[52, 66]. Since PRH interacts with PML as well as with 
PML-RARα [66], PML-RARa is likely to interfere with 
both endogenous PRH and PML activity, promoting leu-
kaemogenesis [57].
More recently it has been demonstrated that PRH can 
function as an oncogene in AML. PRH mRNA expression 
has been noted to be elevated in microarray studies from 
a variety of human AML samples. Moreover high PRH 
mRNA expression correlates with poor survival [70]. 
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Importantly, PRH knockout in a mouse model of AML 
where the AML is initiated by expression of a MLL-ENL 
fusion protein showed that PRH is required for the ini-
tiation and maintenance of the leukaemia and functions 
alongside HOXA9-Meis1 as a transforming oncoprotein 
[70]. PRH recruits Polycomb co-repressor complexes to 
bring about the repression of a set of genes with protein 
products including the cell cycle inhibitors p16-INK4 
and p19-ARF. This repression is essential to maintain the 
leukaemic blasts [70]. Hence targeting PRH is a potential 
therapeutic approach for MLL-ENL dependent AML and 
may also be relevant for other AML where PRH mRNA 
expression is elevated.
Thus it appears that in some situations alteration of 
endogenous PRH protein levels or nuclear localisation 
can contribute to AML whereas in others oncogenic 
transformation leading to elevated PRH mRNA expres-
sion can result in AML. The cell type that is transformed, 
that is whether transformation occurs in a differentiated 
cell or a progenitor/stem cell might account for these 
apparent contradictions. The complexity of PRH involve-
ment in AML is underscored by the finding that PRH is 
directly involved in the initiation of at least one AML 
without involvement of additional transforming proteins 
[65]. In this case a cytogenetic abnormality generated 
the fusion of nucleoporin 98 and PRH (Nup98-HHEX), 
where the N-terminal domain of PRH was substituted 
by that of Nup98, culminating in the emergence of a leu-
kaemogenic gene expression profile [65]. Transplantation 
of murine bone marrow cells expressing Nup98-HHEX 
into transgenic mice resulted in acute leukaemia though 
with a latency period of 9  months, suggesting that the 
translocation is a pre-requisite for disease induction but 
not in itself sufficient for leukaemogenesis [65].
PRH can also act as an oncogene in a subtype of T-cell 
acute lymphoblastic leukaemia known as early T-cell 
precursor-like ALL (ETP-ALL). PRH can phenocopy 
the Lmo2 oncoprotein in inducing self-renewal when 
overexpressed in mice and elevated PRH causes a T-cell 
leukemia, which is strikingly similar to that caused by 
Lmo2. These results suggested that PRH is an important 
mediator of Lmo2-driven T-cell self-renewal and leuke-
mia [41, 67, 71]. Moreover Lmo2-transgenic mice with 
conditional deletion of Prh/HHEX showed a significantly 
delayed onset of the T-cell leukemia [41]. However, 
recent work showed that deletion of Prh/HHEX does 
not always block Lmo2-induced leukemia indicating that 
these proteins can act via parallel pathways [72]. Inter-
estingly, deletion of PRH in the thymus of Lmo2 trans-
genic mice did result in a reduction in the transplantation 
capacity and the radioresistance of Lmo2-transgenic thy-
mocytes but did not inhibit the development of the leu-
kaemia [72].
PRH in cancer
Down-regulation of PRH protein expression and/or 
aberrant subcellular localisation of PRH are associ-
ated with liver, breast, and thyroid tumours [73–75]. 
PRH expression is lower in Grade III (poorly differenti-
ated) hepatocellular carcinomas (HCC) compared to 
Grade II (well-differentiated) HCC [75]. Moreover, PRH 
over-expression inhibits tumour formation by an HHC 
cell line in nude mice [75]. More recently query of the 
ONCOMINE database for PRH expression in tumour 
samples showed that significantly lower PRH mRNA 
expression occurs in activated B-cell-like diffuse large 
B-cell lymphoma, diffuse large B-cell lymphoma, lung 
adenocarcinoma, thyroid gland papillary carcinoma, 
superficial bladder cancer and pancreatic carcinoma 
[76]. As mentioned above PRH subcellular localisation 
is implicated in tumourigenesis: PRH is present in the 
nucleus and cytoplasm in normal breast epithelial cells, 
but in ductal and lobular breast carcinomas, PRH is 
located predominantly in the cytoplasm [73]. Similarly, 
in normal thyroid tissues and adenomas, PRH protein 
is present in the nucleus and cytoplasm whereas in both 
differentiated and undifferentiated thyroid carcinomas 
PRH is only present in the cytoplasm [74]. These findings 
suggest that PRH function is compromised in multiple 
carcinomas by decreased PRH expression and/or aber-
rant intracellular localisation.
The mechanisms that lead to the down-regulation of 
PRH activity and the processes linking this to tumouri-
genesis are not well understood. However, down-regula-
tion of PRH might result in the misregulation of eIF-4E 
and PML activity in some cells types as described above. 
Similarly, down-regulation of PRH could result increased 
VEGF signalling through derepression of VEGF signal-
ling genes [44]. The importance of this in tumour growth 
is discussed in the following section. However, increased 
VEGF signalling might also increase cell proliferation in 
some cell types as shown in myeloid cells [44]. PRH can 
also alter TGFβ signalling via direct transcriptional regu-
lation of the TGFβ co-receptor Endoglin [49]. The role of 
TGFβ in tumourigenesis is complex and varies depend-
ing on tumour type and stage. TGFβ signals through 
TGFβ type I receptor (TβRI) and TGFβ type II recep-
tors (TβRII). The TβRI receptors possess a cytoplasmic 
domain that phosphorylates intracellular proteins includ-
ing members of the Smad family of transcription factors. 
Endoglin is a TGFβ co-receptor expressed in multiple 
cell types including endothelial cells [77]. Endoglin is 
important in angiogenesis and tumour growth but it also 
regulates cellular proliferation. Since PRH activates tran-
scription of Endoglin, down-regulation of PRH activity 
would be expected to decrease Endoglin levels resulting 
in altered TGFβ signalling and consequent increased cell 
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proliferation. However, Endoglin can also act indepen-
dently of the TGFβ signalling pathway and down-regu-
lation of PRH could also impact on tumourigenesis via 
TGFβ-independent pathways.
PRH activity could also influence tumourigenesis via 
regulation of the oncoprotein c-Myc [76]. c-Myc is a 
transcription factor that promotes cell cycle progression 
and participates in the control of apoptosis, cell differ-
entiation and angiogenesis. c-Myc is important in a vari-
ety of human cancers and the c-Myc gene is frequently 
amplified in tumour cells. One way that c-Myc regulates 
transcription is via the formation of DNA binding het-
erodimers with Max. The N-terminal domain of PRH 
directly interacts with the c-Myc and disrupts the forma-
tion of c-Myc-Max heterodimers [76]. This diminishes 
the cellular activity of the c-Myc resulting in decreased 
cell proliferation [76]. Interestingly, eIF-4E and v-myc 
cooperate to transform primary rodent fibroblasts [78] 
suggesting that down-regulation of PRH could transform 
cells via misregulation of these two targets [76].
PRH and cancer cell migration and invasion
Metastatic secondary tumours formed by disseminated 
cancer cells are responsible for the vast majority of can-
cer-related deaths. Metastasis requires a complex series 
of events leading from the initiation of cell migration 
and invasion into local tissues, entry of cells into vessel 
(intravasation), exit from vessels (extravasation), to the 
formation of micro- and ultimately macro-metastases. 
This is facilitated by a change in cell morphology and 
behaviour known as epithelial-mesenchymal transi-
tion (EMT), which involves simultaneous loss of epi-
thelial cell features, such as E-cadherin expression, and 
the acquisition of mesenchymal properties, including 
protease secretion and increased cell mobility/invasive-
ness. PRH regulates several genes that are important in 
EMT, cell migration and cell invasion, including VEGF 
signalling genes, Goosecoid, Endoglin, and ESM-1 [10, 
24, 43, 44]. Tumour-related neo-angiogenesis induced 
by VEGF signalling is pivotal for tumour growth as it 
provides nutrients and oxygen whilst eliminating waste 
products. Any upregulation of VEGF signalling brought 
about by decreased PRH activity would be expected 
to increase tumour growth. We and others have shown 
that PRH directly represses transcription of Goosecoid, 
a known inducer of EMT in breast tumour cells [10, 24, 
79]. In addition, PRH activates transcription of Endog-
lin, a TGFβ co-receptor that can down-regulate TGFβ-
dependent cellular responses [49]. Since TGFβ can 
induce EMT in some cells, the activation of Endoglin 
transcription by PRH would be expected to inhibit EMT. 
Recent work is consistent with this hypothesis since the 
activation of Endoglin expression by PRH inhibits the 
migration of prostate and breast cancer cells and the 
invasion of extracellular matrix [49]. ESM-1 is a derma-
tan sulfate proteoglycan and increased serum levels of 
this protein are associated with highly vascularized meta-
static tumours and a poor prognosis in lung cancer and 
kidney cancer [80]. PRH directly represses ESM-1 tran-
scription suggesting that the disruption of PRH activity is 
likely to be important for ESM-1-related neoangiogenesis 
[43].
Altered regulation of PRH by CK2
Aberrant CK2 expression or activity is thought to be 
oncogenic in non-small cell lung cancer [81], head and 
neck cancer [82], prostate cancer [83], breast cancer [84, 
85] and kidney cancer [86]. CK2 also exhibits oncogenic 
co-operativity with c-Myc and Ha-Ras, enhancing cell 
transformation [87–89]. CK2-mediated abrogation of 
tumour suppressor activity has been demonstrated to 
play a significant role in tumourigenesis. Phosphorylation 
by CK2 inactivates the tumour suppressor proteins, PML, 
connexin, and phosphatase and tensin homology protein 
(PTEN) [90]. For example, phosphorylation of PML S517 
by CK2 facilitates proteasome-dependent proteolysis of 
PML and substitution of S517 with non-phosphorylata-
ble alanine or pharmacological inhibition of CK2 inhibits 
tumourigenesis in  vivo by increasing PML protein lev-
els [90]. Interestingly, phosphorylation of PRH S163 and 
S177 by CK2 results in increased cleavage of PRH by the 
proteasome, and the consequent misregulation of PRH 
target genes [55]. Moreover, inhibition of CK2 or sub-
stitution of S163 and S177 with non-phosphorylatable 
cysteine residues restores PRH function. This suggests 
that CK2 inhibitors could restore PRH function in dis-
ease states that show down-regulation of PRH activity 
such as breast cancer, liver cancer and thyroid cancer and 
thereby restore normal cell functions. Similarly, kinases 
that regulate CK2 could be targeted in order to inhibit 
CK2 and thereby restore PRH function. Our recent work 
has shown that the BCR-ABL/Src kinase inhibitor Dasat-
inib decreases CK2 activity and PRH phosphorylation 
resulting in increased PRH-dependent repression of Vegf 
and Vegfr-1 in leukaemic cells [91]. Since Src activity is 
increased in many cancer types resulting in increased 
CK2 activity, Dasatinib could restore PRH function in 
several disease states.
Concluding remarks
The importance of PRH in tumourigenesis and tumour 
progression is beginning to be more widely appreciated. 
Altered PRH levels and altered PRH subcellular localisa-
tion are associated with several cancers and with some 
subtypes of leukaemia. Moreover, PRH inhibits the abil-
ity of normal epithelial cells to proliferate, migrate and 
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invade surrounding tissue implying that the loss of PRH 
will be important in multiple disease states. These data 
suggest that PRH could be a useful biomarker in cancer 
diagnosis and/or prognosis and an important target in 
some forms of leukaemia. Importantly, PRH is required 
for the sensitivity of some leukaemic cells to Dasatinib, 
an indirect inhibitor of CK2 activity, and is important 
in the response of these cells to the direct inhibition of 
CK2. This suggests that PRH levels and/or pPRH levels 
may be of value in the choice of cancer treatment options 
in a variety of contexts. However, PRH is post-transla-
tionally modified in cells as well as being cleaved by the 
proteasome. Some of the modified and processed forms 
of PRH have altered regulatory activities and thus a vari-
ety of PRH proteins are present in cells with potentially 
contrasting activities. Stringently characterised antibod-
ies generated to recognise different forms of PRH are 
therefore urgently required as well as clinical studies that 
evaluate the value of the different forms of PRH in cancer 
diagnosis and prognosis.
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